NCT04138420View on ClinicalTrials.gov

Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab

CompletedOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

January 25, 2017

Primary Completion Date

October 25, 2017

Study Completion Date

October 30, 2017

Conditions
Exudative Age-related Macular Degeneration
Interventions
DRUG

Bevacizumab Injection

Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)

Trial Locations (1)

80100

"University of Naples Federico II", Naples

All Listed Sponsors
lead

Federico II University

OTHER

NCT04138420 - Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab | Biotech Hunter | Biotech Hunter